Downmodulation of peripheral MOG-specific immunity by pVAXhsp65 treatment during EAE does not reach the CNS

Author(s)

Goncalves Zorzella-Pezavento, Sofia Fernanda ^[1] ; Chiuso-Minicucci, Fernanda ^[1] ; Donega Franca, Thais Graziela ^[1] ; Watanabe Ishikawa, Larissa Lumi ^[1] ; da Rosa, Larissa Camargo ^[1] ; Colavite, Priscila Maria ^[1] ; Marques, Camila ^[2] ; Valerio Ikoma, Maura Rosane ^[2] ; Silva, Celio Lopes ^[3] ; Sartori, Alexandrina ^[1]

Affiliation

^[1] Univ Estadual Paulista UNESP, Dept Microbiol & Immunol, Biosci Inst, BR-18618970 Sao Paulo - Brazil

^[2] Fundacao Dr Amaral Carvalho, Lab Citometria Fluxo, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Dept Biochem & Immunol, Sao Paulo - Brazil

• Document type: Journal article
• Source: Journal of Neuroimmunology; v. 268, n. 1-2, p. 35-42, MAR 15 2014.
• Web of Science Citations: 4

Abstract

Most of the therapeutic strategies to control multiple sclerosis are directed to immune modulation and inflammation control. As heat shock proteins are able to induce immunoregulatory T cells, we investigated the therapeutic effect of a genetic vaccine containing the mycobacterial hsp65 gene on experimental autoimmune encephalomyelitis (EAE). Although pVAXhsp65 was immunogenic for mice with EAE and downmodulated specific cytokine induction by MOG, therapy was not able to decrease clinical severity nor to modify immunologic parameters in the CNS. These results indicate that hsp65, administered as a DNA vaccine, was not therapeutic for EAE. (C) 2014 Elsevier B.V. All rights reserved. (AU)

• FAPESP's process: 11/07528-5 - Prophylactic and therapeutic strategies to control experimental autoimmune encephalomyelitis based on hsp65 immunoregulatory effect
• Grantee: Alexandrina Sartori
• Support Opportunities: Regular Research Grants